HK1246673A1 - 用於預防和治療急性腎損傷的肽 - Google Patents

用於預防和治療急性腎損傷的肽

Info

Publication number
HK1246673A1
HK1246673A1 HK18106280.6A HK18106280A HK1246673A1 HK 1246673 A1 HK1246673 A1 HK 1246673A1 HK 18106280 A HK18106280 A HK 18106280A HK 1246673 A1 HK1246673 A1 HK 1246673A1
Authority
HK
Hong Kong
Prior art keywords
peptide
prevention
treatment
acute renal
renal injury
Prior art date
Application number
HK18106280.6A
Other languages
English (en)
Inventor
Hazel Szeto
Diane Felson
Original Assignee
Univ Cornell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cornell filed Critical Univ Cornell
Publication of HK1246673A1 publication Critical patent/HK1246673A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK18106280.6A 2008-02-26 2018-05-15 用於預防和治療急性腎損傷的肽 HK1246673A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3158508P 2008-02-26 2008-02-26

Publications (1)

Publication Number Publication Date
HK1246673A1 true HK1246673A1 (zh) 2018-09-14

Family

ID=41013650

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15102987.4A HK1202429A1 (zh) 2008-02-26 2015-03-24 用於防止和治療急性腎損傷的方法
HK18106280.6A HK1246673A1 (zh) 2008-02-26 2018-05-15 用於預防和治療急性腎損傷的肽

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK15102987.4A HK1202429A1 (zh) 2008-02-26 2015-03-24 用於防止和治療急性腎損傷的方法

Country Status (7)

Country Link
US (9) US8143219B2 (zh)
EP (3) EP3741381B1 (zh)
JP (5) JP5677096B2 (zh)
CN (4) CN106975070A (zh)
DK (1) DK2262520T3 (zh)
HK (2) HK1202429A1 (zh)
WO (1) WO2009108695A2 (zh)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100506841C (zh) 2003-05-01 2009-07-01 科内尔研究基金会 将分子递送到细胞的方法和载体复合物
EP3549594A1 (en) 2005-09-16 2019-10-09 Cornell Research Foundation, Inc. Aromatic-cationic peptide for use in a method for reducing cd36 expression
EP3741381B1 (en) * 2008-02-26 2024-04-24 Cornell University A peptide for use for prevention and treatment of acute renal injury
EP3906933A1 (en) * 2009-03-20 2021-11-10 The General Hospital Corporation d/b/a Massachusetts General Hospital D-arg-2'6'-dimethyltyrosine-lys-phe-nh2 for use in the prevention of secondary complications of burn injuries
EP2464371B1 (en) * 2009-08-12 2016-03-16 Cornell University Methods for preventing or treating metabolic syndrome
EP4302829A3 (en) * 2009-08-24 2024-03-27 Stealth BioTherapeutics Inc. Peptide for use in preventing or treating macular degeneration
EP2764871A1 (en) * 2009-10-05 2014-08-13 Cornell University Methods for the prevention or treatment of heart failure
EP3269380A1 (en) * 2009-12-31 2018-01-17 Stealth Peptides International, Inc. Methods for the prevention or treatment of vessel occlusion injury
CA2786066A1 (en) 2009-12-31 2011-07-07 Stealth Peptides International, Inc. Methods for performing a coronary artery bypass graft procedure
CN104725472A (zh) * 2010-01-25 2015-06-24 康奈尔大学 芳香族阳离子肽及其用途
US8382672B2 (en) * 2010-03-12 2013-02-26 Claire Andrews Macro/micro duty cycle devices, systems, and methods employing low-frequency ultrasound or other cyclical pressure energies
EP3560508A1 (en) 2010-03-15 2019-10-30 Stealth Peptides International, Inc. Combination therapies using cyclosporine and aromatic cationic peptides
EP2942354A1 (en) * 2010-05-03 2015-11-11 Stealth Peptides International, Inc. Aromatic-Cationic Peptides and Uses of Same
WO2012092238A1 (en) * 2010-12-31 2012-07-05 Zeus Scientific, Inc. Improved methods for determining cell viability using molecular nucleic acid-based techniques
EP2688579A4 (en) * 2011-03-24 2015-10-21 Univ Cornell AROMATIC-CATIONIC PEPTIDES AND USES THEREOF
US20120315281A1 (en) * 2011-05-13 2012-12-13 The Penn State Research Foundation Treatment of renal injury
WO2013021093A1 (es) * 2011-08-10 2013-02-14 Digna Biotech, S.L. Uso de la cardiotofina-1 para el tratamiento de enfermedades renales
AU2012315586B2 (en) * 2011-09-29 2017-07-20 Mayo Foundation For Medical Education And Research Aromatic-cationic peptides and methods for using same
JP6346092B2 (ja) * 2011-10-17 2018-06-20 コーネル ユニヴァーシティー 芳香族カチオン性ペプチドおよびその使用
WO2013074966A1 (en) * 2011-11-17 2013-05-23 The Administrators Of The Tulane Educational Fund Use of pituitary adenylate cyclase activating polypeptide (pacap) and pacap analogs for treating contrast -indused nephropathy
EP3466439A1 (en) * 2011-12-09 2019-04-10 Stealth Peptides International, Inc. Aromatic-cationic peptides and uses of same
CA2865317A1 (en) * 2012-02-22 2013-08-29 Stealth Peptides International, Inc. Methods and compositions for preventing or treating ophthalmic conditions
AU2013222237B2 (en) 2012-02-23 2017-10-05 Cornell University Aromatic-cationic peptides and uses of same
US9636378B2 (en) * 2012-03-30 2017-05-02 Stealth Biotherapeutics Corp Methods and compositions for the prevention and treatment neuropathy
US20150246092A1 (en) * 2012-10-22 2015-09-03 Stealth Peptides International, Inc. Methods for reducing risks associated with heart failure and factors associated therewith
EP3673913A1 (en) * 2013-03-01 2020-07-01 Stealth Biotherapeutics Corp Methods for the treatment of mitochondrial disease
DK2961420T3 (da) * 2013-03-01 2019-10-07 Stealth Biotherapeutics Corp Fremgangsmåder og sammensætninger til forebyggelsen eller behandlingen af barth syndrom
CA2916977A1 (en) 2013-06-26 2014-12-31 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
WO2015089316A1 (en) * 2013-12-12 2015-06-18 Cornell University Methods for preventing and treating oral cancers
US10905818B2 (en) * 2014-03-31 2021-02-02 Zoll Medical Corporation Blood filtering of inflammatory biomarkers to treat post-resuscitation syndrome
ES2869430T3 (es) 2014-06-25 2021-10-25 Flamma Spa Procedimiento para preparar D-arginil-2,6-dimetil-L-tirosil-L-lisil-L-fenilalaninamida
US10112976B2 (en) 2014-06-30 2018-10-30 Flamma S.P.A. Process for the production of D-arginyl-2,6-dimethyl-L-tyrosyl-L-lysyl-L-phenylalaninamide
US10744178B2 (en) 2014-08-21 2020-08-18 Stealth Biotherapeutics Corp Methods and compositions for the prevention and treatment of disease
CA3020393A1 (en) 2016-04-11 2017-10-19 Carnot, Llc Chiral peptides
CN107644976B (zh) * 2016-07-22 2020-09-29 清华大学 锂离子电池电极
EP4378457A3 (en) 2016-11-21 2024-07-31 Saghmos Therapeutics, Inc. Prevention and/or treatment of contrast-induced acute kidney injury
JP7097436B2 (ja) 2017-10-03 2022-07-07 ザ・ユナイテッド・ステイツ・オブ・アメリカ・アズ・リプリゼンテッド・バイ・ザ・セクレタリー・デパートメント・オブ・ヘルス・アンド・ヒューマン・サービシーズ エバンスブルー誘導体の化学的コンジュゲートおよびそれらの放射線治療剤および造影剤としての使用
WO2020018381A1 (en) 2018-07-18 2020-01-23 The Regents Of The University Of California Kidney injury treatment
CN109946139A (zh) * 2019-02-28 2019-06-28 东南大学 一种石蜡切片免疫组化套染pas试剂盒及其染色方法和应用
CN111686239B (zh) * 2019-03-11 2021-12-24 中国科学院微生物研究所 抗真菌化合物的应用
WO2020214518A1 (en) * 2019-04-18 2020-10-22 Arcuate Therapeutics, Inc. Methods of treating renal conditions using peptides that improve mitochondrial function
CN110250110A (zh) * 2019-07-11 2019-09-20 南京医科大学附属逸夫医院 一种顺铂所致急性肾损伤的小鼠模型的构建方法
EP3771467A1 (en) 2019-07-30 2021-02-03 Fundacio Institut de Recerca de l'Hospital de la Santa Creu i sant Pau Ss-31 for the prevention and/or treatment of aneurysm
CN113209294B (zh) * 2020-02-05 2023-06-13 复旦大学 Dor激动剂在制备对抗肾脏纤维化药物中的应用
CN111419860A (zh) * 2020-03-19 2020-07-17 长春市儿童医院 一种肾小球分叶状肾病造模方法
WO2021206316A1 (ko) 2020-04-08 2021-10-14 압타바이오 주식회사 조영제 유발 급성 신부전 치료제
KR102308991B1 (ko) 2020-04-08 2021-10-06 압타바이오 주식회사 조영제 유발 급성 신부전 치료제
CN111933006B (zh) * 2020-07-30 2022-06-03 四川大学华西医院 一种模拟巨噬细胞改善小鼠急性肾损伤实验的方法及系统
CN116390723A (zh) 2020-09-09 2023-07-04 社会利益网络公司 用于将生物素递送至线粒体的方法和组合物
IL301305A (en) * 2020-09-11 2023-05-01 Renibus Therapeutics Inc A method for treating cancer while protecting the kidneys

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
EP0350221B1 (en) 1988-06-30 1996-04-17 Astra Aktiebolag Dermorphin analogs, their methods of preparation, pharmaceutical compositions, and methods of therapeutic treatment using the same
US5602100A (en) 1988-06-30 1997-02-11 Astra Ab Dermorphin analogs having pharmacological activity
US5674980A (en) 1989-12-21 1997-10-07 Biogen Inc Fusion protein comprising tat-derived transport moiety
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
WO1994028012A1 (en) * 1993-05-28 1994-12-08 Warner-Lambert Company Hydroxamate inhibitors of endothelin converting enzyme
IS4261A (is) 1994-02-21 1995-08-22 Astra Aktiebolag Nýir peptíð-ópíóíðar til meðhöndlunar á verkjum og notkun þeirra
DE69630918T2 (de) 1995-06-09 2004-10-28 Hisamitsu Pharmaceutical Co., Inc., Tosu Matrix für Iontophorese
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US5885958A (en) 1997-03-25 1999-03-23 Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
WO1999029721A1 (en) 1997-12-10 1999-06-17 Washington University Anti-pathogen system and methods of use thereof
EP1071414A1 (en) 1998-04-24 2001-01-31 Mitokor Compounds and methods for treating mitochondria-associated diseases
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
SE9900961D0 (sv) 1999-03-16 1999-03-16 Astra Ab Novel compounds
CA2386540A1 (en) 1999-10-04 2001-04-12 University Of Medicine And Dentistry Of New Jersey Novel carbamates and ureas
US6759520B1 (en) 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US20050192215A1 (en) 2000-01-21 2005-09-01 Malabika Ghosh Methods and materials relating to novel polypeptides and polynucleotides
ES2398039T3 (es) 2000-03-09 2013-03-13 Genzyme Corporation Uso de anticuerpos antagonistas anti-TGF-beta para tratar o prevenir la pérdida de función renal
US7498297B2 (en) 2000-07-18 2009-03-03 Cornell Research Foundation Medicinal uses of mu-opioid receptor agonists
US6900178B2 (en) 2000-09-12 2005-05-31 University Of Kentucky Research Foundation Protection against ischemia and reperfusion injury
NZ529308A (en) 2001-04-05 2005-03-24 Collagenex Pharm Inc Tetracycline compounds comprising a tetracycline and a controlled release agent to provide delivery at a dose below that required for antibiotic activity
US20070015146A1 (en) * 2001-05-22 2007-01-18 Gene Logic, Inc. Molecular nephrotoxicology modeling
EP3842055A1 (en) 2003-02-04 2021-06-30 Cornell Research Foundation, Inc. Uses of aromatic-cationic peptide
CN100506841C (zh) 2003-05-01 2009-07-01 科内尔研究基金会 将分子递送到细胞的方法和载体复合物
US7232824B2 (en) 2003-09-30 2007-06-19 Scios, Inc. Quinazoline derivatives as medicaments
US7550439B2 (en) 2004-01-23 2009-06-23 Cornell Research Foundation, Inc. Methods for reducing oxidative damage
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
EP3549594A1 (en) 2005-09-16 2019-10-09 Cornell Research Foundation, Inc. Aromatic-cationic peptide for use in a method for reducing cd36 expression
US20080027082A1 (en) * 2006-06-19 2008-01-31 Berthold Hocher Use of adenosine a1 antagonists in radiocontrast media induced nephropathy
EP3741381B1 (en) * 2008-02-26 2024-04-24 Cornell University A peptide for use for prevention and treatment of acute renal injury

Also Published As

Publication number Publication date
EP3741381B1 (en) 2024-04-24
CN107802821A (zh) 2018-03-16
JP5677096B2 (ja) 2015-02-25
US8143219B2 (en) 2012-03-27
EP3741381A1 (en) 2020-11-25
US20130017150A1 (en) 2013-01-17
EP3243521A1 (en) 2017-11-15
JP2016175924A (ja) 2016-10-06
US20150353602A1 (en) 2015-12-10
US8940696B2 (en) 2015-01-27
CN101951936A (zh) 2011-01-19
US20230398172A1 (en) 2023-12-14
JP2011513241A (ja) 2011-04-28
US8592373B2 (en) 2013-11-26
CN106975070A (zh) 2017-07-25
WO2009108695A2 (en) 2009-09-03
JP2019059785A (ja) 2019-04-18
EP2262520A4 (en) 2012-02-29
EP2262520B1 (en) 2017-05-03
US20180177840A1 (en) 2018-06-28
US20210023161A1 (en) 2021-01-28
EP2262520A2 (en) 2010-12-22
HK1202429A1 (zh) 2015-10-02
US11628198B2 (en) 2023-04-18
EP3243521B1 (en) 2020-05-27
DK2262520T3 (en) 2017-08-07
US20090221514A1 (en) 2009-09-03
CN104056248A (zh) 2014-09-24
US20140107033A1 (en) 2014-04-17
JP2015063561A (ja) 2015-04-09
WO2009108695A3 (en) 2009-12-30
JP2017226697A (ja) 2017-12-28
US20190388492A1 (en) 2019-12-26
US20170112893A1 (en) 2017-04-27

Similar Documents

Publication Publication Date Title
HK1246673A1 (zh) 用於預防和治療急性腎損傷的肽
IL210589A (en) C2386RV Protein Tuberculosis Kvfb Protein Use for the Treatment or Prevention of TB
EP2004630A4 (en) 2-AMINOPYRIMIDIN-4-ONES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF PATHOLOGIES RELATED TO PROTEIN A
HK1164766A1 (zh) 種植物大麻素或其組合用於治療癲癇症之用途
GB0803018D0 (en) Therapeutic compounds and their use
IL209895A (en) Compounds for the prevention and / or treatment of β-amyloidoses
EP2249854A4 (en) IMPROVED TREATMENT AND PROPHYLAXIS
EP2412297A4 (en) ENDOSCOPE OF A TYPE OF CASE FOR TREATMENT, AND ENDOSCOPE CASE
GB0804685D0 (en) Therapeutic compounds and their use
EP2170311A4 (en) COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING AUTOIMMUNE DISEASES
EP2215017A4 (en) IMPROVED CLEANING AND TREATMENT DEVICE
GB0807609D0 (en) Therapeutic compounds and their use
IL221276A (en) Combination with Sigma ligand and opioids or opiates for prevention or treatment of pain that develops as a result of surgery
GB201100311D0 (en) Nasal device for obesity prevention and treatment
GB0817208D0 (en) Therapeutic apsap compounds and their use
HK1167592A1 (zh) 環十縮酚酸肽化合物及其作為藥物的用途
EP2140884A4 (en) VACCINE FOR THE PREVENTION AND / OR TREATMENT OF AUTOIMMUNE DISEASES
ZA201101752B (en) A medicinal product and treatment
GB0908868D0 (en) Depsipeptide and their therapeutic use
GB0816650D0 (en) Therapeutic bone grwth and regeneration
GB0812913D0 (en) Therapeutic compounds and their use
IL210428A (en) Apadnosone dosing unit and method of use
HK1130434A1 (en) Treatment and prevention of excessive scarring
GB0802128D0 (en) Therapeutic compounds and their use
GB0815134D0 (en) Therapeutic compounds and their use